Genmab (GMAB)
(Delayed Data from NSDQ)
$21.78 USD
+0.11 (0.51%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $21.78 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
B Value C Growth C Momentum B VGM
Key Expected Earnings Data
Report Date | Period Ending | Zacks Consensus Estimate | Earnings ESP |
---|---|---|---|
08/07/2025
Time: BMO |
6/2025 | $0.39 | 10.03% |
Earnings Summary
For their last quarter, Genmab (GMAB) reported earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.23 per share. This reflects a positive earnings surprise of 34.78%. Look out for GMAB's next earnings release on August 07, 2025. For the next earning release, we expect the company to report earnings of $0.39 per share, reflecting a year-over-year increase of 77.27%.
Earnings History
Price & Consensus
Zacks News for GMAB
Will Escalating Medical Costs Dampen Centene's Q2 Earnings?
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
GMAB FAQs
Genmab A/S Sponsored ADR (GMAB) has announced they will report their next quarter earnings on August 07, 2025. For the next earning release, we expect the company to report earnings of $0.39 per share, reflecting a year-over-year increase of 77.27%.
Genmab A/S Sponsored ADR has announced they will report their previous quarter earnings after the close of the market on August 07, 2025.
The Zacks Consensus Estimate for Genmab A/S Sponsored ADR (GMAB) for the quarter ending in June 2025 is $0.39 a share. We expect Genmab A/S Sponsored ADR to miss by 10.03%.
In the earnings report for the quarter ending in June 2024, Genmab A/S Sponsored ADR (GMAB) announced earnings of $0.22 per share versus the Zacks Consensus Estimate of $0.29 per share, representing a surprise of -24.14%.